The open-label, dose-escalation and expansion study, titled "A Phase 1/2 Study of ML-016 in Participants with Advanced Cancer ...
Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) have ...
TORL BioTherapeutics LLC (TORL), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, ...
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific ADC ...
While sentiment in the local biotech sector is improving, a plethora of smaller revenue-generating stocks remain deeply ...
September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, ...
TPU researchers together with their colleagues have developed a new analytical model of heating and evaporation of binary ...
Learn more about whether Ligand Pharmaceuticals Incorporated or Tilray Brands, Inc. is a better investment based on AAII's A+ ...
Scientists created the first working quantum money system that cannot be counterfeited using light particles and quantum ...
Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback